Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026
Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates…
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl…
Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR…
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress on September 4, 2025
Vivoryon Therapeutics N.V. to Report H1 2025 Financial Results and Operational Progress…
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conferences Halle (Saale) /…
